Showing results (391-400 of 12,935) with videos related to
Sort By:
Pageof 1,294
Nature Reviews. Cardiology|July 27, 2026
Cardioprotective properties of empagliflozin and other SGLT2 inhibitorsThomas A Zelniker, Eugene BraunwaldAmerican Heart Journal|October 12, 2010
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Christian T Ruff, Robert P Giugliano, Elliott M Antman, et al.European Heart Journal. Acute Cardiovascular Care|July 25, 2018
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.Journal of Thrombosis and Thrombolysis|January 1, 1995
Optimizing the Treatment of Unstable AnginaCannonAmerican Heart Journal|February 10, 2016
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trialAlon Eisen, Robert P Giugliano, Christian T Ruff, et al.European Heart Journal|June 30, 2007
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG studyBenjamin M Scirica, David A Morrow, Zygmunt Sadowski, et al.European Journal of Heart Failure|March 29, 2023
Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillationKazuma Oyama, Robert P Giugliano, Christian T Ruff, et al.American Heart Journal|January 6, 2022
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroupsBaris Gencer, Alon Eisen, David Berger, et al.Circulation. Cardiovascular Quality and Outcomes|May 12, 2018
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction)James Aisenberg, Prapti Chatterjee-Murphy, Kathryn Friedman Flack, et al.Pageof 1,294